{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:54:23Z","timestamp":1792806863168,"version":"4.5.0"},"reference-count":87,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Center for Infection Research (DZIF)","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"https:\/\/ror.org\/028s4q594","id-type":"ROR","asserted-by":"crossref"}]},{"name":"BMBF initiative 676 \u201cNaFoUniMedCovid19\u201c","award":["FKZ: 01KX2021 (subprojects B-FAST and COVIM)"],"award-info":[{"award-number":["FKZ: 01KX2021 (subprojects B-FAST and COVIM)"]}]},{"DOI":"10.13039\/100009103","name":"Von-Behring-R\u00f6ntgen-Stiftung","doi-asserted-by":"publisher","award":["66-0031"],"award-info":[{"award-number":["66-0031"]}],"id":[{"id":"10.13039\/100009103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009103","name":"Von-Behring-R\u00f6ntgen-Stiftung","doi-asserted-by":"publisher","award":["68-0003"],"award-info":[{"award-number":["68-0003"]}],"id":[{"id":"10.13039\/100009103","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Loewe Research Center DRUID","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Despite the recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the global fight against the SARS-CoV-2 pandemic due to their ability to convey immediate protection and their potential to be used as both prophylactic and therapeutic drugs. Clinically used neutralizing antibodies against respiratory viruses are currently injected intravenously, which can lead to suboptimal pulmonary bioavailability and thus to a lower effectiveness. Here we describe DZIF-10c, a fully human monoclonal neutralizing antibody that binds the receptor-binding domain of the SARS-CoV-2 spike protein. DZIF-10c displays an exceptionally high neutralizing potency against SARS-CoV-2, retains full activity against the variant of concern (VOC) B.1.1.7 and still neutralizes the VOC B.1.351, although with reduced potency. Importantly, not only systemic but also intranasal application of DZIF-10c abolished the presence of infectious particles in the lungs of SARS-CoV-2 infected mice and mitigated lung pathology when administered prophylactically. Along with a favorable pharmacokinetic profile, these results highlight DZIF-10c as a novel human SARS-CoV-2 neutralizing antibody with high in vitro and in vivo antiviral potency. The successful intranasal application of DZIF-10c paves the way for clinical trials investigating topical delivery of anti-SARS-CoV-2 antibodies.<\/jats:p>","DOI":"10.3390\/v13081498","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T21:21:21Z","timestamp":1627593681000},"page":"1498","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4021-7728","authenticated-orcid":false,"given":"Sandro","family":"Halwe","sequence":"first","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Hans-Meerwein-Stra\u00dfe 2, 35043 Marburg, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8517-4779","authenticated-orcid":false,"given":"Alexandra","family":"Kupke","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Hans-Meerwein-Stra\u00dfe 2, 35043 Marburg, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4552-9170","authenticated-orcid":false,"given":"Kanika","family":"Vanshylla","sequence":"additional","affiliation":[{"name":"Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1557-2621","authenticated-orcid":false,"given":"Falk","family":"Liberta","sequence":"additional","affiliation":[{"name":"Biotherapeutics Discovery, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0725-7138","authenticated-orcid":false,"given":"Henning","family":"Gruell","sequence":"additional","affiliation":[{"name":"Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5745-0836","authenticated-orcid":false,"given":"Matthias","family":"Zehner","sequence":"additional","affiliation":[{"name":"Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4752-8326","authenticated-orcid":false,"given":"Cornelius","family":"Rohde","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Hans-Meerwein-Stra\u00dfe 2, 35043 Marburg, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Kr\u00e4hling","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Hans-Meerwein-Stra\u00dfe 2, 35043 Marburg, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-3555","authenticated-orcid":false,"given":"Michelle","family":"Gellhorn Serra","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Hans-Meerwein-Stra\u00dfe 2, 35043 Marburg, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-9850","authenticated-orcid":false,"given":"Christoph","family":"Kreer","sequence":"additional","affiliation":[{"name":"Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2750-3252","authenticated-orcid":false,"given":"Michael","family":"Kl\u00fcver","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Hans-Meerwein-Stra\u00dfe 2, 35043 Marburg, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Sauerhering","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Hans-Meerwein-Stra\u00dfe 2, 35043 Marburg, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3168-2254","authenticated-orcid":false,"given":"J\u00f6rg","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Hans-Meerwein-Stra\u00dfe 2, 35043 Marburg, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Cai","sequence":"additional","affiliation":[{"name":"Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Han","sequence":"additional","affiliation":[{"name":"Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Young","sequence":"additional","affiliation":[{"name":"Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangwei","family":"Yang","sequence":"additional","affiliation":[{"name":"Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-9307","authenticated-orcid":false,"given":"Marek","family":"Widera","sequence":"additional","affiliation":[{"name":"Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt am Main, 60596 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2962-7814","authenticated-orcid":false,"given":"Manuel","family":"Koch","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany"},{"name":"Institute for Dental Research and Oral Musculoskeletal Biology and Center for Biochemistry, University of Cologne, 50931 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9316-0227","authenticated-orcid":false,"given":"Anke","family":"Werner","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Hans-Meerwein-Stra\u00dfe 2, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"K\u00e4mper","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Hans-Meerwein-Stra\u00dfe 2, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Becker","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Hans-Meerwein-Stra\u00dfe 2, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Marlow","sequence":"additional","affiliation":[{"name":"Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Eickmann","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Hans-Meerwein-Stra\u00dfe 2, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-7565","authenticated-orcid":false,"given":"Sandra","family":"Ciesek","sequence":"additional","affiliation":[{"name":"Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt am Main, 60596 Frankfurt am Main, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Frankfurt am Main, 60596 Frankfurt am Main, Germany"},{"name":"Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch Translational Medicine and Pharmacology, 60596 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Schiele","sequence":"additional","affiliation":[{"name":"Biotherapeutics Discovery, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-1792","authenticated-orcid":false,"given":"Florian","family":"Klein","sequence":"additional","affiliation":[{"name":"Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany"},{"name":"Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 50931 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6621-9350","authenticated-orcid":false,"given":"Stephan","family":"Becker","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Hans-Meerwein-Stra\u00dfe 2, 35043 Marburg, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"ref_1","unstructured":"Johns Hopkins Coronavirus Resource Center (2021, July 06). COVID-19 United States Cases by County\u2014Johns Hopkins Coronavirus Resource Center. Available online: https:\/\/coronavirus.jhu.edu\/map."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/314523","article-title":"Reduction of Respiratory Syncytial Virus (RSV) in Tracheal Aspirates in Intubated Infants by Use of Humanized Monoclonal Antibody to RSV F Protein","volume":"178","author":"Malley","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","article-title":"Structures and distributions of SARS-CoV-2 spike proteins on intact virions","volume":"588","author":"Ke","year":"2020","journal-title":"Nature"},{"key":"ref_11","first-page":"285","article-title":"Neutralizing antibodies against SARS-CoV-2: Current understanding, challenge and perspective","volume":"3","author":"Huang","year":"2020","journal-title":"Antib. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41467-020-20602-5","article-title":"A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein","volume":"12","author":"Kim","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cell.2020.06.011","article-title":"A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies","volume":"182","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1854149","DOI":"10.1080\/19420862.2020.1854149","article-title":"Anti-SARS-CoV-2 neutralizing monoclonal antibodies: Clinical pipeline","volume":"12","author":"Tuccori","year":"2020","journal-title":"mAbs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.addr.2020.12.004","article-title":"Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy","volume":"169","author":"Tiruthani","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2020.06.044","article-title":"Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients","volume":"182","author":"Kreer","year":"2020","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4161\/mabs.2.6.13333","article-title":"Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats","volume":"2","author":"Khawli","year":"2010","journal-title":"mAbs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.xphs.2016.04.027","article-title":"Evaluation of Heavy-Chain C-Terminal Deletion on Product Quality and Pharmacokinetics of Monoclonal Antibodies","volume":"105","author":"Jiang","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2020.01.010","article-title":"Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody","volume":"180","author":"Schommers","year":"2020","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11654","DOI":"10.1128\/JVI.01815-15","article-title":"A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform","volume":"89","author":"Malczyk","year":"2015","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8651","DOI":"10.1128\/JVI.00614-15","article-title":"Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein","volume":"89","author":"Volz","year":"2015","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Sauerhering, L., Kupke, A., Meier, L., Dietzel, E., Hoppe, J., Gruber, A.D., Gattenloehner, S., Witte, B., Fink, L., and Hofmann, N. (2020). Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus via interferon-\u03bb in vitro and in mice. Eur. Respir. J., 56.","DOI":"10.1183\/13993003.01826-2019"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e2026207118","DOI":"10.1073\/pnas.2026207118","article-title":"Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination","volume":"118","author":"Tscherne","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Crawford, K.H.D., Eguia, R., Dingens, A.S., Loes, A.N., Malone, K.D., Wolf, C.R., Chu, H.Y., Tortorici, M.A., Veesler, D., and Murphy, M. (2020). Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses, 12.","DOI":"10.1101\/2020.04.20.051219"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.chom.2021.04.015","article-title":"Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans","volume":"29","author":"Vanshylla","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_35","unstructured":"Collier, D.A., de Marco, A., Ferreira, I.A.T.M., Meng, B., Datir, R., Walls, A.C., Kemp, S.S.A., Bassi, J., Pinto, D., and Fregni, C.S. (2021). SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies. medRxiv."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wibmer, C.K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B.E., de Oliveira, T., Vermeulen, M., and van der Berg, K. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med.","DOI":"10.1101\/2021.01.18.427166"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Widera, M., Wilhelm, A., Hoehl, S., Pallas, C., Kohmer, N., Wolf, T., Rabenau, H.F., Corman, V., Drosten, C., and Vehreschild, M.J. (2021). Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro. medRxiv.","DOI":"10.1101\/2021.02.24.21252372"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wang, P., Nair, M.S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., and Kwong, P.D. (2021). Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature.","DOI":"10.1038\/s41586-021-03398-2"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","article-title":"Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates","volume":"2","author":"Wang","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nmeth.2115","article-title":"Prevention of overfitting in cryo-EM structure determination","volume":"9","author":"Sjors","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymeth.2013.07.005","article-title":"Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies","volume":"65","author":"Proetzel","year":"2014","journal-title":"Methods"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"16538","DOI":"10.1073\/pnas.1315295110","article-title":"HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice","volume":"110","author":"Horwitz","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Wan, Y., Shang, J., Graham, R., Baric, R.S., and Li, F. (2020). Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J. Virol., 94.","DOI":"10.1128\/JVI.00127-20"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","article-title":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice","volume":"583","author":"Bao","year":"2020","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4049\/jimmunol.2000583","article-title":"A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection","volume":"205","author":"Alsoussi","year":"2020","journal-title":"J. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","article-title":"Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment","volume":"182","author":"Sun","year":"2020","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1080\/22221751.2020.1838955","article-title":"Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection","volume":"9","author":"Rathnasinghe","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1128\/JVI.00671-11","article-title":"Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent Fc\u03b3R pathway","volume":"85","author":"Jaume","year":"2011","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/infdis\/jit504","article-title":"Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: Implications for pathogenesis","volume":"209","author":"Zhou","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/infdis\/jit123","article-title":"Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC\/2012: Implications for disease pathogenesis and clinical manifestation","volume":"207","author":"Chan","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-2600(20)30193-4","article-title":"Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: An analysis in ex-vivo and in-vitro cultures","volume":"8","author":"Hui","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Boumaza, A., Gay, L., Mezouar, S., Bestion, E., Diallo, A.B., Michel, M., Desnues, B., Raoult, D., La Scola, B., and Halfon, P. (2021). Monocytes and macrophages, targets of SARS-CoV-2: The clue for Covid-19 immunoparalysis. J. Infect. Dis.","DOI":"10.1101\/2020.09.17.300996"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Finkelstein, M.T., Mermelstein, A.G., Parker Miller, E., Seth, P.C., Stancofski, E.-S.D., and Fera, D. (2021). Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Viruses, 13.","DOI":"10.3390\/v13010134"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.chom.2020.06.010","article-title":"Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike","volume":"28","author":"Huo","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41594-020-0480-y","article-title":"Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient","volume":"27","author":"Zhou","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","article-title":"Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1126\/science.abc5881","article-title":"Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody","volume":"369","author":"Lv","year":"2020","journal-title":"Science"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"Corman","year":"2020","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Dagotto, G., Mercado, N.B., Martinez, D.R., Hou, Y.J., Nkolola, J.P., Carnahan, R.H., Crowe, J.E., Baric, R.S., and Barouch, D.H. (2021). Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques. J. Virol.","DOI":"10.1128\/JVI.02370-20"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1111\/bph.15143","article-title":"Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology","volume":"177","author":"Cleary","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19","volume":"586","author":"Dowling","year":"2020","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1128\/AAC.00290-15","article-title":"Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies","volume":"59","author":"Tan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1128\/jvi.61.6.1851-1854.1987","article-title":"Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats","volume":"61","author":"Prince","year":"1987","journal-title":"J. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/infdis\/174.2.256","article-title":"Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection","volume":"174","author":"Weltzin","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"100218","DOI":"10.1016\/j.xcrm.2021.100218","article-title":"Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters","volume":"2","author":"Piepenbrink","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/S0264-410X(02)00247-5","article-title":"Tracking the tissue distribution of marker dye following intranasal delivery in mice and chinchillas: A multifactorial analysis of parameters affecting nasal retention","volume":"20","author":"Visweswaraiah","year":"2002","journal-title":"Vaccine"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Ku, Z., Xie, X., Hinton, P.R., Liu, X., Ye, X., Muruato, A.E., Ng, D.C., Biswas, S., Zou, J., and Liu, Y. (2021). Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature, 1\u20136.","DOI":"10.1038\/s41586-021-03673-2"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Ladel, S., Flamm, J., Zadeh, A.S., Filzwieser, D., Walter, J.-C., Schlossbauer, P., Kinscherf, R., Lischka, K., Luksch, H., and Schindowski, K. (2018). Allogenic Fc Domain-Facilitated Uptake of IgG in Nasal Lamina Propria: Friend or Foe for Intranasal CNS Delivery?. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10030107"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Ladel, S., Maigler, F., Flamm, J., Schlossbauer, P., Handl, A., Hermann, R., Herzog, H., Hummel, T., Mizaikoff, B., and Schindowski, K. (2020). Impact of Glycosylation and Species Origin on the Uptake and Permeation of IgGs through the Nasal Airway Mucosa. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12111014"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.immuni.2004.05.007","article-title":"Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells","volume":"20","author":"Yoshida","year":"2004","journal-title":"Immunity"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C.O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., and Lieberman, J.A. (2021). mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature.","DOI":"10.1101\/2021.01.15.426911"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J.C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., and Michailidis, E. (2020). Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife, 9.","DOI":"10.7554\/eLife.61312"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","article-title":"A perspective on potential antibody-dependent enhancement of SARS-CoV-2","volume":"584","author":"Arvin","year":"2020","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Quinlan, B.D., He, W., Mou, H., Zhang, L., Guo, Y., Chang, J., Peng, S., Ojha, A., Tavora, R., and Parcells, M.S. (2020). An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines. bioRxiv Prepr. Serv. Biol.","DOI":"10.1101\/2020.11.18.388934"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/infdis\/jiw171","article-title":"Genome-wide Chromatin Profiling of Legionella pneumophila-Infected Human Macrophages Reveals Activation of the Probacterial Host Factor TNFAIP2","volume":"214","author":"Marsico","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Herkt, C.E., Caffrey, B.E., Surmann, K., Blankenburg, S., Gesell Salazar, M., Jung, A.L., Herbel, S.M., Hoffmann, K., Schulte, L.N., and Chen, W. (2020). A MicroRNA Network Controls Legionella pneumophila Replication in Human Macrophages via LGALS8 and MX1. mBio, 11.","DOI":"10.1128\/mBio.03155-19"},{"key":"ref_81","unstructured":"Chand, M., Hopkins, S., Dabrera, G., Achison, C., Barclay, W., Ferguson, N., Volz, E., Loman, N., Rambaut, A., and Barrett, J. (2020). Investigation of novel SARS-COV-2 variant, Variant of Concern 202012\/01, PHE Gateway Number: GW-1824."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E.J., and Msomi, N. (2020). Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv.","DOI":"10.1101\/2020.12.21.20248640"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"112958","DOI":"10.1016\/j.jim.2021.112958","article-title":"Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies","volume":"490","author":"Halwe","year":"2021","journal-title":"J. Immunol. Methods"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Hierholzer, J.C., and Killington, R.A. (1996). Virus isolation and quantitation. Virol. Methods Man., 25\u201346.","DOI":"10.1016\/B978-012465330-6\/50003-8"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2000045","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","article-title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","volume":"25","author":"Corman","year":"2020","journal-title":"Eurosurveillance"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"20285","DOI":"10.2807\/ese.17.39.20285-en","article-title":"Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction","volume":"17","author":"Corman","year":"2012","journal-title":"Eurosurveillance"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1498\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:37:04Z","timestamp":1760164624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":87,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["v13081498"],"URL":"https:\/\/doi.org\/10.3390\/v13081498","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.06.09.447662","asserted-by":"object"}]},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,29]]}}}